Stable Isotope Labeled Compounds Market Leading Players and Business Intelligence
According to the new market research report Stable Isotope Labeled Compounds Market
is projected to grow at a CAGR of 3.0% during the forecast period to
reach USD 312 million by 2024 from USD 269 million in 2019.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=53034199
The
growth of this market is driven majorly by the increase in research
activities in the pharmaceutical and biotechnology sector, the rising
prevalence of cancer, and rising proteomics research. However, the high
cost of stable isotope-labeled compounds is expected to restrain the
growth of this market during the forecast period.
Cambridge
Isotope Laboratories (CIL) (US), Merck KGaA (Germany), and URENCO (UK)
are the key players operating in the stable isotope labeled compounds
market. Other prominent players in the market include IsoSciences, LLC
(US), Medical Isotopes, Inc. (US), Omicron Biochemicals, Inc. (US),
Trace Sciences International (US), Alsachim (France), Taiyo Nippon Sanso
Corporation (Japan), and Rotem Industries Israel Ltd. (Israel).
Cambridge
Isotope Laboratories (CIL) held the leading position in the stable
isotope labeled compounds market in 2018. The company offers a
comprehensive portfolio of stable isotope-labeled compounds for
laboratories; medical, government, and academic research centers; and
healthcare facilities. The company offers more than 15,000 products and
has ISO 13485, ISO/IEC 17025, and ISO Guide 34 quality systems, along
with cGMP production capabilities. Over the years, the company has
extended its global footprint in four countries—the US, Canada, France,
and Germany. The CIL group comprises five companies—Cambridge Isotope
Laboratories, Inc. (CIL) (US), CIL Isotope Separations, LLC (CIS) (US),
CIL Canada (Canada), Euriso-Top (France), and ABX GmbH (Germany). All
these facilities are dedicated to various stages of stable
isotope-labeled compound production. The company’s isotope separation
facility located in Ohio (US) is the world’s largest C-13 and O-18
isotope separation facility and has the only commercial heavy enrichment
columns in the world.
With the acquisition of Sigma-Aldrich
Corporation (US), Merck KGaA secured the second position in the global
stable isotope labeled compounds market in 2018. Sigma-Aldrich was one
of the leading developers, manufacturers, and distributors of stable
isotope-labeled compounds. Its acquisition made Merck a leader in the
global life science industry, valued at more than USD 113 billion (EUR
100 billion). In addition, the acquisition considerably expanded Merck’s
geographic footprint, especially in North America. Merck KGaA designs
and manufactures products for academic research markets, applied testing
customers, the pharmaceutical & biotechnology industry, and
molecular diagnostics laboratories.
Merck operates in three
business sectors—Healthcare, Life Sciences, and Performance Materials.
The healthcare business unit comprises the Biopharma, Consumer Health,
Allergopharma, and Biosimilars businesses. The company has an enormous
product range of more than 300,000 life science products sold under the
SAFC, BioReliance, Millipore, and Milli-Q brands, among others. Merck is
present in North America, Europe, the Asia Pacific, Latin America, and
the Middle East & Africa, with ~50,000 employees working at 72
production locations across 66 countries. The firm has 130 global
distribution centers. Acquisitions, collaborations, expansions, a broad
product portfolio, and the presence of a strong distribution and sales
network across the globe have enabled this company to secure a leading
position in the stable isotope labeled compounds market.
Based on
type, the stable isotope labeled compounds industry is segmented into
C-13, N-15, O-18, H-2 (deuterium), and other isotopes. The H-2 labeled
compounds segment accounted for the largest share of the stable
isotope-labeled compounds market in 2019.
Based on application,
the stable isotope labeled compounds market is segmented into research,
clinical diagnostics, industrial applications, and other applications.
Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=53034199
North
America is expected to dominate the stable isotope labeled compounds
market. The major factors driving the growth of this market include the
growth of the pharmaceutical and biopharmaceutical industry, the large
nuclear industry in the US, the growth of the Canadian pharmaceutical
industry, and the availability of funding in North American countries.
North America is also expected to register the highest CAGR during the
forecast period.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com
Comments
Post a Comment